Search for: "Par Pharmaceutical, Inc."
Results 61 - 80
of 148
Sort by Relevance
|
Sort by Date
21 May 2013, 2:26 pm
Earlier this month, the Department of Justice announced a $500 million settlement it reached with Ranbaxy USA Inc., a subsidiary of the Indian generic pharmaceutical manufacturer Ranbaxy Laboratories Limited. [read post]
11 Apr 2013, 4:57 am
FTC Sues Regarding AndroGel Patent SettlementThe Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-replacement drug AndroGel, a prescription pharmaceutical with annual sales of more than… [read post]
2 Apr 2013, 2:48 pm
Last month, Par Pharmaceutical Companies Inc. pleaded guilty to federal criminal charges and agreed to settle civil allegations involving the company’s promotion of the drug Megace ES. [read post]
2 Apr 2013, 1:55 pm
Last month, Par Pharmaceutical Companies Inc. pleaded guilty to federal criminal charges and agreed to settle civil allegations involving the company’s promotion of the drug Megace ES. [read post]
13 Mar 2013, 4:45 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
11 Mar 2013, 8:12 am
New Jersey-based Par Pharmaceutical Companies Inc. [read post]
5 Mar 2013, 1:56 am
On March 5, the Department of Justice announced that generic drug maker Par Pharmaceuticals, Inc., entered a guilty plea and agreed to pay a combined $45 million to settle criminal and civil charges that it promoted Megace ES off-label. [read post]
11 Feb 2013, 6:00 am
Of course self-insured employers do not set out to get sub-par results from the adjusters. [read post]
7 Feb 2013, 10:50 am
Par Pharmaceutical, Inc., 694 F.3d 1344, 1351 (Fed. [read post]
15 Jan 2013, 11:33 am
Companies Agree to Sell Rights to 18 Drugs to Satisfy FTCThe Federal Trade Commission will require Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive.... [read post]
19 Oct 2012, 6:13 pm
The majority of the assets in these 18 markets would be divested to Par Pharmaceutical, Inc. [read post]
18 Oct 2012, 1:00 am
Par Pharmaceutical Inc., the Federal Circuit upheld the district court’s determination that the patents at issue were not invalid as obvious and were infringed by the subject Abbreviated New Drug Applications (ANDAs). [read post]
13 Sep 2012, 9:59 pm
Par Pharmaceutical, Inc., thereby allowing Santarus to keep Par's generic version of Zegerid® off the market until the expiration of the Orange Book-listed patents. [read post]
11 Sep 2012, 5:30 am
Par Pharmaceutical, Inc., which dealt with whether a drug covered by an Abbreviated New Drug Application (ANDA) infringed the patents owned by that patent owner relative to the proton pump inhibitors (PPI) product omeprazole. [read post]
5 Sep 2012, 5:51 pm
IPNews® - The Federal Circuit on Tuesday partially reversed a lower court's finding that a number of Santarus Inc.'s patent claims for its heartburn drug Zegerid are invalid, giving Santarus another crack at hanging Par Pharmaceuticals Inc. out to dry for trying to market a generic version of the drug. [read post]
5 Sep 2012, 5:45 pm
California - The Federal Circuit on Tuesday gave Santarus Inc. another chance to prove that its patents for the heartburn drug Zegerid are valid and that Par Pharmaceuticals Inc.'s proposed generic version would infringe those patents. [read post]
25 Apr 2012, 1:56 pm
Watson Pharmaceuticals, Inc., No. 10-12729, is available here. [read post]
19 Apr 2012, 8:17 pm
Inc. v. [read post]
15 Apr 2012, 8:47 pm
• Defendants: Par Pharmaceutical Companies Inc.; Par Pharmaceutical Inc. [read post]
23 Feb 2012, 4:11 pm
On October 14, 2011, Par Pharmaceutical, Inc. [read post]
